Recent progress of sodium glucose cotransporter 2 inhibitors in treatment of heart failure with preserved ejection fraction

Heart failure is a serious manifestation or late stage of various heart diseases with high mortality and re-hospitalization rate and is becoming one of the important diseases endangering human health. Heart failure with preserved ejection fraction (HFpEF) accounts for more than half of the patients with HF, but currently there is no definitive treatment strategy to reduce the morbidity and mortality of HFpEF. In recent years, the cardiovascular benefits of SGLT-2i, a novel hypoglycemic drug, have been widely concerned and whether HFpEF patients can benefit from SGLT-2I has attracted much attention. This paper will review this issue.